**ABSTRACT**

The oxidative metabolism of 17β-estradiol (E2) and estrone (E1) to catechol estrogens (2-OHE2, 4-OHE2, 2-OHE1, and 4-OHE1) and estrogen quinones has been postulated to be a factor in mammary carcinogenesis. Catechol-O-methyltransferase (COMT) catalyzes the methylation of catechol estrogens to methoxy estrogens, which simultaneously lowers the potential for DNA damage and increases the concentration of 2-methoxyestradiol (2-MeOE2), an antiproliferative metabolite. We expressed two recombinant forms of COMT, the wild-type (108Val) and a common variant (108Met), to determine whether their catalytic efficiencies differ with respect to catechol estrogen inactivation. The His-tagged proteins were purified by nickel-nitriilo-triacetic acid chromatography and analyzed by electrophoresis and Western immunoblot. COMT activity was assessed by determining the methylation of 2-OHE2, 4-OHE2, 2-OHE1, and 4-OHE1, using gas chromatography/mass spectrometry for quantitation of the respective methoxy products. In the case of 2-OHE2 and 2-OHE1, methylation occurred at 2-OH and 3-OH groups, resulting in the formation of 2-MeOE2 and 2-OH-3-MeOE2, and 2-MeOE1 and 2-OH-3-MeOE1, respectively. In contrast, in the case of 4-OHE2 and 4-OHE1, methylation occurred only at the 4-OH group, yielding 4-MeOE2 and 4-MeOE1, respectively. Individual and competition experiments revealed the following order of product formation: 4-MeOE2 > 4-MeOE1 >> 2-MeOE2 > 2-OHE1 > 2-OH-3-MeOE1 > 2-OH-3-MeOE2. The variant isoform differed from wild-type COMT by being thermolabile, leading to 2–3-fold lower levels of product formation. MCF-7 breast cancer cells with the variant COMT 108Met/Met genotype also displayed 2–3-fold lower catalytic activity than ZR-75 breast cancer cells with the wild-type COMT 108Val/Val genotype. Thus, inherited alterations in COMT catalytic activity are associated with significant differences in catechol estrogen and methoxy estrogen levels and, thereby, may contribute to interindividual differences in breast cancer risk associated with estrogen-mediated carcinogenicity.

**INTRODUCTION**

COMT is an enzyme that catalyzes the transfer of a methyl group from the methionyl donor SAM to one hydroxyl moiety of the catechol ring of a substrate (1). Physiological substrates of COMT include catecholamine neurotransmitters and the catechol estrogens, produced by cytochrome P-450-mediated metabolism of E2 and E1 (2, 3). Cell fractionation and immunological studies have shown that the enzyme occurs in two distinct forms, in the cytoplasm as a soluble protein (S-COMT) and in association with membranes as a membrane-bound form (MB-COMT; Refs. 4–6). The amino acid sequence of S-COMT and MB-COMT is identical, except for an NH2-terminal extension of 50 hydrophobic amino acids in MB-COMT that serves as an anchor to the membrane (7, 8). Genetic studies have demonstrated that S-COMT and MB-COMT are encoded by a single gene at 22q11.2 containing six exons, of which exons 1 and 2 are noncoding. A proximal promoter gives rise to the 1.3-kb S-COMT mRNA, whereas a distal promoter gives rise to the 1.5-kb MB-COMT mRNA (9). The MB-COMT and S-COMT proteins occur constitutively but differ in tissue expression. S-COMT is the predominant form in virtually all tissues, whereas MB-COMT generally accounts for ~10% of total enzyme activity (4, 10). For example, S-COMT constituted >90% of total COMT activity in normal breast tissue as well as MCF-7 breast cancer cells (9).

Lachman et al. (11) identified a G→A polymorphism in the COMT gene that is associated with a valine→methionine substitution in both the MB-form (codon 158) and S-form (codon 108). Using 3,4-dihydroxybenzoic acid as substrate, Syvanen et al. (12) determined that COMT activity in red blood cells from individuals with the homozygous Met/Met genotype was ~60% lower than that of homozygous Val/Val individuals, i.e., 0.21–0.43 versus 0.55–1.03 pmol·min^-1·mg^-1 protein. Heterozygotes showed intermediate activity. Although it is likely that the Val→Met polymorphism also affects catechol estrogen metabolism, it is not known whether the effect is similar for each of the four main catechol estrogens, i.e., 2-OHE2, 2-OHE1, 4-OHE2, and 4-OHE1. It will be important to answer this question because experimental and epidemiological evidence suggests that the COMT-mediated reaction holds significant implications for estrogen-induced carcinogenesis and breast cancer development:

(a) Two of three molecular epidemiological studies indicate that the Val/Val, Val/Met, and Met/Met genotypes may be associated with differences in risk of developing breast cancer (13–15). Another study linked COMT genotypes to progression of breast cancer to the metastatic state (16).

(b) By inactivating catechol estrogens, COMT reduces the level of 2-OH and 4-OH estrogen metabolites, thereby lowering the potential for mutagenic damage through DNA adduct formation or through superoxide and hydroxy radicals arising from catechol estrogen quinone-semiquinone redox cycling (17, 18).

(c) 2-MeOE2, which is produced by COMT from 2-OHE2, has been shown to inhibit the proliferation of breast cancer cells in vitro and in vivo (19, 20). The inhibitory effect of 2-MeOE2 appears to be attributable to several mechanisms including the disruption of mitochondrial function, induction of apoptosis, and inhibition of angiogenesis (21–24). Oral administration of 2-MeOE2 (75 mg/kg) for 1 month suppressed the growth of human breast cancer in mice by 60% without toxicity (25). Thus, 2-MeOE2 (but not 4-MeOE2) appears to be an endogenous estrogen metabolite that inhibits mammary carcinogenesis (26).

In light of these considerations, we have cloned and expressed the wild-type and variant forms of COMT to determine whether the catalytic efficiency of the Met variant differs from that of the Val wild type with regard to the inactivation of E2 versus E1 catechol estrogens, the inactivation of 2-OH versus 4-OH metabolites, singly and in combination, and the rate of production of 2-MeOE2 from 2-OHE2.
We have also compared the activities of wild-type and variant COMT in breast cancer cell lines ZR-75 and MCF-7, respectively.

MATERIALS AND METHODS

**Chemicals.** Catechol estrogens (2-OHE2, 2-OHE1, 4-OHE2, and 4-OHE1) and methoxyestrogens (2-MeO2E, 2-MeOE1, 4-MeOE2, 4-MeOE1, 2-OH-3-MeOE2, 2-OH-3-MeOE1, 2-MeO-3-MeOE2, and 2-MeO-3-MeOE1) were obtained from Steroidolx (Newport, RI). Deuterated E2 (E2-2, 4, 16, and 16-d4) was obtained from CDN Isotopes (Pointe-Claire, Quebec, Canada).

**Cell Lines.** Breast cancer cell lines ZR-75 and MCF-7 were obtained from the American Type Culture Collection (Rockville, MD) and grown under recommended culture conditions. DNA was isolated using a DNA extraction kit (Genta, Minneapolis, MN).

**DNA Polymorphism Analysis.** COMT was amplified with primers C1 (5'-GGCCGCATCATCACCAGCGATGGATTTGCGTGCTC) and C2 (5'-GTCTTCAGTGAAGGCTTGTTG). PCR was carried out in a total volume of 100 μl containing 0.5 μg of genomic DNA, 10 μm Tris-HCl (pH 8.3), 50 μM KCl, 1.5 mM MgCl2, 200 μM each of the four deoxynucleobases, AmpliTaq DNA polymerase (2.5 units; Roche Diagnostics, Indianapolis, IN), and each primer at 25 μM. Amplification conditions consisted of an initial denaturing step followed by 30 cycles of 95°C for 30 s, 64°C for 1 min, and 72°C for 6 min. A sample of the 160-bp PCR product was size fractionated by electrophoresis in a 1.5% agarose gel and visualized by ethidium bromide staining. A portion (10 μl) of the PCR product was subjected to restriction digest with EcoRI (New England Biolabs, Beverly, MA) at 37°C for 1 h. The digestion products were electrophoresed in a 4% low melting agarose gel (Amresco, Solon, OH) and visualized by ethidium bromide staining.

**Expression and Purification of Recombinant S-COMT.** Breast cancer cell lines ZR-75 (Val/Val) and MCF-7 (Met/Met) served as source for wild-type and variant S-COMT cDNA, respectively. Primers were designed to contain ScFv and satellite sites, respectively, at their 5’ ends to allow amplification of wild-type and variant S-COMT cDNA and ligation of the PCR product into vector pQE-30 (QIAGEN, Valencia, CA), which encodes an NH2-terminal vector pCANTAB5E phagemid vector (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). Expressed ScFv display a tag recognized by the Pharmacia Anti-E tag and HRP/Anti-E tag monoclonal antibodies. The Anti-E tag antibody can be used to detect ScFv bound to antigens in assays and can also be used to affinity-purify ScFv from bacterial extracts. Initial selections with purified His-ScFv did not yield ScFv antibodies with sufficient affinity for use in immunassays. Therefore, we attached another tag, GST using the plasmid pGEX-4T (Amersham Pharmacia Biotech, Inc.) to produce the recombinant purified fusion protein COMT-GST. Three rounds of phage antibody selection were performed using one ml of COMT-GST immobilized on Nunc Maxisorb tubes at 100 μg of COMT-GST/ml PBS for the first round, 10 μg/ml for the second round, and 1 μg/ml for the third round of selection (28). Tubes and phage antibodies were blocked in 0.09-0.1% Tween 20 in PBS to prior selections. Phage antibodies were eluted from COMT-GST-coated tubes with 1 ml of 100 mM triethanolamine for the first two rounds of selection and with 100 mM triethanolamine for the third round. Eluted phage antibodies were used to infect E. coli TG1 cells, which served as bacterial source for phage-displayed or soluble recombinant antibody production.

**ICELISA to Determine ScFv Antigen Specificity.** The ICELISA protocol, which accompanies Amersham Pharmacia’s HRP/Anti-E tag conjugate, was used to detect and determine antigen specificity of ScFv produced by bacterial colonies. All assays were carried out in 384-well microtitrers plates with individual wells either left uncoated or coated with 50 μl of COMT-GST, His-COMT, or GST at 5 μg/ml PBS.

**Preparation and Purification of ScFv from Bacterial Periplasmic Extracts.** Bacteria were grown overnight at 30°C in 250 ml of 2xYT medium with 100 μg/ml ampicillin and 2% glucose with shaking at 100 rpm. Bacteria were centrifuged to pellet cells, resuspended in 2xYT medium with 100 μg/ml ampicillin and 1 mM isopropyl-β-D-thiogalacto-pyranoside, incubated, and centrifuged as before. To prepare periplasmic extracts, bacterial pellets were resuspended sequentially in 10 ml of TES [0.2 M Tris-HCl (pH 8.0), 0.5 mM EDTA, and 0.5 M sucrose] and 15 ml of one-fifth TES [0.04 M Tris-HCl (pH 8.0), 0.1 mM EDTA, and 0.1 M sucrose] and placed on ice for 1 h or at ~70°C until needed. Recombinant ScFv were purified from periplasmic extracts by affinity chromatography using an Amersham Pharmacia RPAS Purification Module according to the manufacturer’s instructions.

**Western Immunoblot of COMT.** Purified recombinant His-COMT and COMT in breast cancer cell cytosol were resolved by SDS polyacrylamide gel electrophoresis and transferred to nitrocellulose. Nitrocellulose filters were blocked for 1 h with 3% nonfat dry milk in PBS (3% NFDM). The HRP/Anti-E tag conjugate was diluted 1:4,000 in 3% NFDM, mixed with an equal volume ScFv in periplasmic extract, applied to COMT samples on nitrocellulose blots, and incubated for 1 h at room temperature. Blots were washed for 30 min in PBS containing 0.05% Tween 20 and then visualized on film using an HRP-enhanced chemiluminescent substrate.

**Competitive ICELISA to Quantify ScFv.** On the basis of preliminary assays, six bacterial clones produced ScFv that interacted with COMT-GST and His-COMT but not with GST. The ScFv bacterial clone designated C3 was selected based on optimal absorbance readings at 405 nm: 2.646 (COMT, C3) with optimal absorbance readings at 405 nm: 2.646 (COMT, C3) with optimal absorbance readings at 405 nm: 2.646 (COMT, C3) with optimal absorbance readings at 405 nm: 2.646 (COMT, C3) with optimal absorbance readings at 405 nm: 2.646 (COMT, C3) with optimal absorbance readings at 405 nm. The ICELISA was carried out at room temperature in a 384-well microtiter plate coated with purified COMT-GST at 0.5 μg/ml PBS, 50 μl/well. Wells were emptied, filled with PBS containing 0.1% Tween 20 (PBST) and blocked for 15 min. Known concentrations of COMT-GST were mixed with C3-HRP/Anti-E immune complex (composed of purified C3, diluted to 2.7 μg/ml, and HRP/Anti-E conjugate, diluted 1:8,000 in 3% NFDM) to obtain a standard curve. Cytosol samples containing COMT were diluted 1:10 in C3-HRP/Anti-E immune complex. After a 90-min incubation, samples and C3-HRP/Anti-E immune complex standards were added in duplicate to the COMT-GST-coated microtiter wells, at 50 μl/well. After a 1-h incubation, wells were washed seven times with PBS containing 0.05% Tween 20. Wells were tapped dry, and 50 μl of 2.2’-azino-bis(3-ethylthiazol-6-sulfonic acid) and hydrogen peroxide were added for color development and absorbance readings at 405 nm using a BIO-TEK ELX800NB plate reader (BIO-TEK Instruments, Inc., Winooski, VT). The plate reader’s KCjw software was used to generate a standard curve, based on a four-parameter fit, and to calculate COMT concentrations in samples.
Fig. 1. Total ion chromatogram illustrating the separation of an equimolar mixture of estrogens, their metabolites, and the desired internal standard (d4E2). The vertical dotted lines indicate the position of the three different ion collection groups: 9–24.2 min (m/z 229, 257, 285, 287, 314, 315, 342, 343, 372, 373, 416, 417, and 420); 24.2–26.5 min (m/z 257, 315, 342, 372, 373, 388, 389, 430, 431, 432, 446, and 447); and 26.2–31 min (m/z 283, 309, 311, 314, 345, 373, 414, 430, 431, 446, 447, 504, and 505). The inset shows the single-ion chromatograms (m/z 446, 414, 430, and 504) for the area within the dashed line on the total ion chromatogram where the peaks overlap. All compounds except 2-MeO-3-MeOE1 are chromatographed as TMS derivatives. The chromatography conditions are given in the text.

Thermal Inactivation. COMT thermal stability was measured as described by Scanlon et al. (29). Specifically, aliquots of recombinant wild-type and variant COMT were heated at 48°C for 15 min while control samples were kept on ice. The heated samples were returned to ice before measurement of enzyme thermal activity. Thermal stabilities were expressed as H:C ratios, a commonly used measure of enzyme thermal stability (30, 31).

Extraction and Gas Chromatography/Mass Spectrometry Analysis of Catechol Estrogens. A deuterated internal standard (100 μl of 8 mg/ml E2-d4 in methanol) was added, and all estrogens were extracted into the CH2Cl2 by vortex mixing for 30 s. The CH2Cl2 fraction (1.5 ml) was evaporated to dryness under air, and volatile TMS derivatives were prepared by heating the residue with 100 μl of 50% NO-bis(trimethylsilyl)trifluoroacetamide/1% trimethylchlorosilane in acetonitrile at 56°C for 30 min. The TMS derivatives of the estrogen metabolites were separated by gas chromatography (H-P 5890, Hewlett-Packard, Wilmington, DE) on a 5% phenyl methyl silicone stationary phase fused silica capillary column (30 m × 0.2 mm × 0.5 μm film, HP5; Hewlett-Packard). Helium carrier gas was used at a flow of 1 ml/min. The injector was operated at 250°C, with 2 μl injected in the splitless mode, with a purge (60 ml/min helium) time of 0.6 min. The oven temperature was held at 180°C for 0.5 min, then raised to 6°C/min to 250°C where it was held for 17 min, then raised to 300°C at 8°C/min to give a total run time of 35.42 min. This program permitted adequate separation of a wide range of estrogen metabolites. Retention times (in min) for the TMS derivatives were: E1, 20.13; E2 and E2-d4, 21.89; 4-MeOE1, 23.52; 2-MeO-3-MeOE1 (underativated), 23.75; 2-OH-3-MeOE1, 24.87; 2-MeOE1, 25.2; 4-MeOE2, 25.78; 2-OHE1 and 2-MeO-3-MeOE2, 26.19; 2-OH-3-MeOE2, 26.9; 2-MeOE2, 27.18; 4-OHE1, 27.27; 6α-OHE1, 27.29; 2-OHE2, 27.44; 4-OHE2, 28.06; and E3, 28.38. The EI mass spectrometer (H-P 5970) was operated in the selected ion monitoring mode from 18 to 30 min. Ions monitored were TMS-E1, 342, 257, and 343; TMS-E2-d4, 420, 421, and 287; TMS-E2, 416, 417, and 285; TMS-4-MeOE1, TMS-2-OH-3-MeOE1, TMS-2-MeOE1, and TMS-3-MeO-4-OHE1, 372, 373, and 342; 2-MeO-3-MeOE1, 314, 315, and 229; TMS-4-MeOE2, TMS-2-OH-3-MeOE2, TMS-2-MeOE2, and TMS-3-MeO-4-OHE2, 446, 447, and 315; TMS-2-OHE1 430, 389, and 432; TMS-2-MeOE3, TMS-3-MeOE2, 388, 389, and 257; TMS-3-OHE1, 430, 389, and 345; TMS-6α-OHE2, 414, 283, and 309; TMS-2-OHE2 and TMS-4-OHE2, 504, 505, and 373; and TMS-E3, 504, 505, and 311 (Fig. 1). The instrument was calibrated by simultaneous preparation of an 11-point calibration over the range 0–22 nmol/tube of each compound. Sensitivity was determined to be between 0.02 and 0.04 nmol/tube (400–800 fmol on column) for the various compounds. Preparation of the TMS derivatives improved chromatography and sensitivity significantly. Derivatization was performed at 56°C because use of a higher temperature resulted in the loss of some estrogen derivatives (particularly the 2-OH metabolite of estrone). Derivatization was demonstrated to be complete at 20 min, as evidenced by the absence of detectable amounts of underivatized estrogens in the highest calibrator when the detector was operated in full scan mode. Absolute extraction efficiency for E2, 2-OH-E2, and 4-OH-E2 at 3.5 nmol/tube was 119, 96, and 107%, assessed by comparison with injections of spiked solvent samples onto the gas chromatogram. Internal standard added prior to extraction compensated for deviation from 100% recovery for all investigated compounds.

Statistical Analysis. Kinetic parameters (Km and kcat) for the enzyme reactions were determined by nonlinear regression analysis using the computer program GraphPad Prism (San Diego, CA).

RESULTS

We performed PCR and restriction endonuclease digestion to identify the wild-type and variant COMT alleles. We introduced a BspHI restriction site into the C1 primer (see “Materials and Methods”; underlined nucleotide) to reveal the methionine allele in codon 108 of the COMT gene. BspHI is a 6-base cutter with a single recognition site on the PCR product of the methionine allele and no site on the valine allele. In contrast, the 4-base cutter NcoII used by Lachman et al. (11) cleaves three sites on the methionine allele and two sites on the valine allele, yielding relatively small restriction fragments of 67 and 71 bp, which are not easily distinguished from each other. Digestion of the COMT PCR product with BspHI yielded bands of 160 bp for the

9, 12, 15, 20, 40, 60, 80, and 100 μM). Blanks contained all compounds except SAM. Reactions proceeded for 10 min at 37°C with gentle shaking and then were terminated by addition of 2 ml of CH3Cl. To determine COMT activity in breast cancer cells, ZR-75 and MCF-7 cells were harvested at confluency and homogenized in 100 mM KPO4 (pH 7.4), 5 mM MgCl2, and 10 mM β-mercaptoethanol. After ultracentrifugation of the cell homogenate (110,000 × g for 30 min at 4°C), the supernatant cytosol was divided into aliquots for IELISA, protein determination (BCA assay; Pierce, Rockford, IL), and COMT assay. The latter was carried out in the presence of 200 μM SAM and 100 μM catechol estrogen for 20 min at 37°C and then terminated by addition of CH3Cl. The concentration of endogenous catechol and methoxy estrogens was below the limit of detection by gas chromatography/mass spectrometry.

We performed PCR and restriction endonuclease digestion to identify the wild-type and variant COMT alleles. We introduced a BspHI restriction site into the C1 primer (see “Materials and Methods”; underlined nucleotide) to reveal the methionine allele in codon 108 of the COMT gene. BspHI is a 6-base cutter with a single recognition site on the PCR product of the methionine allele and no site on the valine allele. In contrast, the 4-base cutter NcoII used by Lachman et al. (11) cleaves three sites on the methionine allele and two sites on the valine allele, yielding relatively small restriction fragments of 67 and 71 bp, which are not easily distinguished from each other. Digestion of the COMT PCR product with BspHI yielded bands of 160 bp for the
Fig. 2. Analysis of COMT gene and protein. A. Analysis of COMT genotypes by PCR amplification and digestion with BspHI, followed by agarose gel electrophoresis, shows bands of 160 bp for the Val/Val genotype (Lane 2), 160, 125, and 35 bp for the Val/Met genotype (Lane 3); and 125 and 35 bp for the Met/Met genotype (Lane 4). The small 35-bp fragment is not visualized on this low melting agarose gel. Lane 1, the molecular size marker. B. SDS-PAGE of purified wild-type and variant COMT subjected to silver staining shows wild-type (Lane 2) and variant (Lane 3) COMT. Lane 1 contains the molecular weight marker. C. Western immunoblot using anti-COMT antibody H6 shows recombinant wild-type COMT (Lane 1), recombinant variant COMT (Lane 2), wild-type COMT in ZR-75 cytosol (Lane 3), and variant COMT in MCF-7 cytosol (Lane 4).

Val/Val genotype; 160, 125, and 35 bp for the Val/Val genotype; and 125 and 35 bp for the Met/Met genotype (Fig. 2A). Breast cancer cell lines ZR-75 (Val/Val) and MCF-7 (Met/Met) served as a source for wild-type and variant S-COMT cDNA, respectively. His-tagged wild-type and variant S-COMTs were expressed and purified by nickel-nitritriacetic acid chromatography. Each recombinant protein was electrophoretically homogeneous as judged by SDS-PAGE and silver staining, which revealed a single band at $M_r$ 25,000 (Fig. 2B). We developed COMT-specific ScFv antibodies to further characterize the recombinant COMT and to demonstrate the presence of wild-type and variant COMT in breast cancer cell lines ZR-75 and MCF-7, respectively. Initial attempts to select for phage-display, COMT-specific ScFv using purified His-COMT yielded antibodies whose affinity was too low for use in immunoassays. Therefore, we prepared recombinant, purified COMT-GST to generate antibodies with greater affinity. The ScFv bacterial clone designated H6 proved optimal, yielding the following ICELISA absorbance readings: 2.551 (COMT-GST), 0.441 (His-COMT), 0.141 (GST), and 0.151 (blank well). The Western immunoblot using anti-COMT antibody H6 showed one major band at $M_r$ 25,000 for recombinant wild-type and variant COMT (Fig. 2C, Lanes 1 and 2). Similarly, wild-type and variant COMT in cytosol of ZR-75 and MCF-7 cells, respectively, migrated predominantly as one band (Fig. 2C, Lanes 3 and 4). However, the cytosol protein migrated slightly higher than the recombinant protein, probably because of posttranslational modification.

COMT activity was assessed by determining the methylation of the substrates 2-OHE2, 4-OHE2, 2-OHE1, and 4-OHE1 (Fig. 3). The reaction kinetics were determined in two replicate experiments at 10 different concentrations of each substrate. The resulting $K_m$ and $k_{cat}$ are presented in Table 1. COMT catalyzed the formation of monomethyl ethers at 2-OH, 3-OH, and 4-OH groups. Dimethyl ethers were not observed. In the case of 2-OHE2 and 2-OHE1, methylation occurred at 2-OH and 3-OH groups, resulting in the formation of 2-MeOE2 and 2-OH-3-MeOE2, and 2-MeOE1 and 2-OH-3-MeOE1, respectively. In contrast, in the case of 4-OHE2 and 4-OHE1, methylation occurred only at the 4-OH group, resulting in the formation of 4-MeOE2 and 4-MeOE1, respectively. 3-MeOE4-OHE2 and 3-MeOE4-OHE1 were not observed. As shown in Fig. 3, the rates of methylation of 2-OHE2 and 2-OHE1 yielded typical hyperbolic patterns, whereas 4-OHE2 and 4-OHE1 exhibited a sigmoid curve pattern. Overall, COMT displayed the highest catalytic efficiencies $k_{cat}/K_m$ in the formation of 4-MeO products (142 and 126 mm$^{-1}$ min$^{-1}$), followed by the 2-MeO products (63 and 45 mm$^{-1}$ min$^{-1}$), and lastly the 3-MeO products (29 and 38 mm$^{-1}$ min$^{-1}$; Table 1). Competition experiments using an equimolar concentration of all four catechol estrogens revealed the following order of product formation: 4-MeOE2 > 4-MeOE1 >> 2-MeOE2 > 2-MeOE1 > 2-OH-3-MeOE1 > 2-OH-3-MeOE2 (Fig. 4). The experimental conditions

**Table 1: Kinetic parameters for COMT-mediated catechol estrogen metabolism**

<table>
<thead>
<tr>
<th>Products</th>
<th>$K_m$ (mM)</th>
<th>$k_{cat}$ (min$^{-1}$)</th>
<th>$k_{cat}/K_m$ (min$^{-1}$)</th>
<th>Hill coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-MeOE2</td>
<td>108 ± 9</td>
<td>6.8 ± 0.4</td>
<td>63 ± 6</td>
<td>NA*</td>
</tr>
<tr>
<td>2-OH-3-MeOE2</td>
<td>51 ± 5</td>
<td>1.5 ± 0.1</td>
<td>29 ± 3</td>
<td>NA</td>
</tr>
<tr>
<td>4-MeOE2</td>
<td>24 ± 3</td>
<td>3.4 ± 0.2</td>
<td>142 ± 20</td>
<td>1.6 ± 0.2</td>
</tr>
<tr>
<td>2-MeOE1</td>
<td>74 ± 8</td>
<td>3.3 ± 0.2</td>
<td>45 ± 6</td>
<td>NA</td>
</tr>
<tr>
<td>2-OH-3-MeOE1</td>
<td>73 ± 6</td>
<td>2.8 ± 0.4</td>
<td>38 ± 10</td>
<td>NA</td>
</tr>
<tr>
<td>4-MeOE1</td>
<td>53 ± 6</td>
<td>6.7 ± 0.4</td>
<td>126 ± 16</td>
<td>2.0 ± 0.4</td>
</tr>
</tbody>
</table>

*NA, not applicable; the best fit was to a Michaelis-Menten curve.
COMT catalyzes the methylation of both 2-OH and 4-OH catechol estrogens to methoxy estrogens. However, our data reveal major differences in the interaction of 2-OHE and 4-OHE substrates with the enzyme. Methylation of 2-OHE substrates exhibits Michaelis-Menten saturation kinetics and yields two products, i.e., 2-methoxy- and 3-methoxyestrogens. In contrast, the methylation of 4-OHE substrates displays sigmoid saturation kinetics indicating cooperative binding and yields only a single product, i.e., 4-methoxyestrogen. COMT-mediated methylation of 4-OHE2 and 4-OHE1 has been proposed as a pathway for the formation of 3-MeO-4-OHE2 and 3-MeO-4-OHE1, respectively (26). Our results show that 3-MeO-4-OHE2 and 3-MeO-4-OHE1 are not formed by COMT. The main structural difference between 2-OH and 4-OH catechol estrogens is the proximity of the 4-OH group to the B ring of the steroid. Clearly, the 2-OH and 3-OH groups in 2-OHE appear to be similar in reactivity, whereas the 3-OH and 4-OH groups in 4-OHE differ in reactivity to the point that in the latter only the 4-OH group becomes methylated. The difference in regiospecific reactivity is not limited to the catechol estrogens but extends to the corresponding quinones. For example, the 2,3-quinone formed from 2-OHE has a half-life of 42 at pH 7.4 and 37°C, whereas the 3,4-quinone formed from 4-OHE has a half-life of 12 min under identical conditions (32). Reactions of 4-methylimidazole with 2,3-estrone quinone and 3,4-estrone quinone also showed greater reactivity and decreased stability of the former (33).

Competitive COMT-catalyzed methylation of equimolar concentrations of 2-OHE2, 4-OHE2, 2-OHE1, and 4-OHE1 yielded preferential formation of 4-MeO products, followed by 2-MeO and 3-MeO products. This order matches that predicted by the experiments with individual catechol estrogens, in which COMT displayed the highest catalytic efficiencies for the formation of 4-MeO products, followed by 2-MeO and 3-MeO products. The difference in regiospecific reactivity of 2-OH and 4-OH catechol estrogens and their respective quinones translates into biological differences with respect to carcinogenicity. Treatment with 4-OHE2 and 4-OHE1, but not 2-OHE2 and 2-OHE1, induced renal cancer in Syrian hamster (34, 35). Analysis of renal DNA demonstrated that 4-OHE2 and 4-OHE1 significantly increased DNA adduct (8-hydroxyguanosine) levels, whereas the corresponding 2-OH catechol estrogens had no effect (36). Similarly, 4-OHE2 induced DNA single-strand breaks whereas 2-OHE2 had a negligible effect (37). Experiments with calf thymus DNA showed that 2,3-quinones preferentially form stable adducts, whereas 3,4-quinones are more likely to produce depurinating adducts (17, 38). When both stable and depurinating adducts were considered, the 3,4-quinones produced a much higher level of binding with DNA (39).

The regiospecific methylation of 2-OH and 4-OH catechol estrogens by COMT influences not only the level of potential DNA damage but also the concentration of 2-MeOE2, an antiproliferative...
metabolite for human breast cancer, lung cancer, and leukemia cells (19, 20, 23, 24). The antiproliferative effect of 2-MeOE2 appears to be concentration dependent and involve several mechanisms. At nanomolar and micromolar concentrations, 2-MeOE2 caused disruption of microtubule function, induction of apoptosis, and inhibition of angiogenesis (21–24). At millimolar concentrations, 2-MeOE2 caused chromosome breaks and aneuploidy (40). Comparison of 2-MeOE2 and 4-MeOE2 showed no antiproliferative action of the latter compound, suggesting that 2-MeOE2 may be the only endogenous estrogen metabolite that inhibits mammary carcinogenesis (26). However, the second O-methylation product of 2-OH2, 2-OH-3-MeOE2, has not been examined, and a systematic comparison of 2-MeOE2 and 2-MeOE1 has not yet been performed.

S-COMT consists of eight α-helices and seven β-strands (41). Residue 108Val, which is located in the turn between α5 and β3, is not part of the coenzyme (SAM), Mg$^{2+}$ ion, or substrate binding sites. Although not directly involved in the methyl transfer reaction, residue 108 appears critically important for overall configuration and stability of the enzyme. The substitution 108Val→Met changes the thermotropic behavior of COMT. Using the H:C ratio as a function of thermal stability and dopamine as a substrate, Lotta et al. (31) observed an 80% reduction in enzyme activity when variant COMT, expressed in E. coli, was incubated for 15 min at 40°C, whereas the wild-type COMT activity remained stable. Our reaction conditions differed from those of Lotta et al. (31) in that we used catechol estrogens as substrates and purified recombinant COMT. Nevertheless, the H:C ratio of the variant enzyme was significantly lower than the ratio of the wild-type enzyme, leading to 2–3-fold lower levels of product formation. These findings indicate that the substitution 108Val→Met renders COMT more thermolabile and thereby lowers enzyme efficiency toward all substrates.

Using 3,4-dihydroxybenzoic acid as substrate, Syvanen et al. (12) showed that COMT activity in RBCs from individuals with the homozygous Met/Met genotype was ~60% lower than that of homozygous Val/Val individuals, i.e., 0.21–0.43 versus 0.55–1.03 pmol·min⁻¹·mg⁻¹ protein. In this study, we used catechol estrogens as physiological substrates and developed an ICELISA to directly measure the COMT concentration in breast cancer cells. Although ZR-75 and MCF-7 contain similar amounts of COMT, they differ in genotype and enzymatic activity. The catalytic activity of variant COMT in MCF-7 cells was 2–3-fold lower than that of wild-type COMT in ZR-75 cells. Because COMT is expressed ubiquitously, it appears that the COMT genotype significantly affects levels of catecholamines and catechol estrogens throughout the body. This means that tissue concentrations of catechol estrogens will differ significantly during the reproductive life of women with variant COMT compared with women with wild-type COMT genotype. Therefore, the exposure to 2-MeOE2 and its purported beneficial effect will be considerably less in women with variant COMT.

In contrast to COMT, the cytochrome P-450 (CYP) enzymes, CYP1A1 and CYP1B1, are expressed in a tissue-specific manner, with high levels in breast and low levels in liver (42, 43). With regard to estrogens, the multifunctional CYP1A1 and CYP1B1 catalyze two sequential reactions in the human breast, i.e., the hydroxylation of E2 and E1 to their respective catechol estrogens, followed by the oxidation of catechol estrogens to estrogen quinones (44, 45). Thus, CYP1A1 and CYP1B1 generate catechol estrogen substrates for COMT, and at the same time, they compete with COMT by converting the catechol estrogens to estrogen quinones. To complicate matters further, CYP1A1 and CYP1B1 differ in catalytic efficiency as estrogen hydroxylases and in their principal site of catalysis with regard to the A ring of the steroid (46–48). CYP1B1 exceeds CYP1A1 in its catalytic efficiency as an estrogen hydroxylase and has its primary activity at the C-4 position, whereas CYP1A1 has its primary activity at the C-2 position in preference to 4-hydroxylation. Thus, CYP1B1 produces mostly 4-OHE2 and 4-OHE1, which are methylated faster by COMT than 2-OHE2 and 2-OHE1, the principal products of CYP1A1. Finally, genetic variants of each of these three enzymes have been identified, some with proven or suspected change in catalytic activity (27, 49–52). For example, the CYP1B1 119Ser variant is about three times more active in converting E2 to 4-OHE2 than wild-type CYP1B1 119Ala (27). In this study, we determined that the COMT 108Met variant is about three times less active in methylating 4-OHE2 to 4-MeOE2 than wild-type CYP1B1 119Ala (27). In this study, we determined that the COMT 108Met variant is about three times less active in methylating 4-OHE2 to 4-MeOE2 than wild-type COMT 108Val. Thus, a hypothetical woman A with the wild-type genotype combination CYP1B1 (119Ala/Ala), COMT (108Val/Val) is likely to be exposed to significantly lower 4-OHE2 levels than woman B with the variant genotype combination CYP1B1 (119Ser/Ser), COMT (108Met/Met). In view of the potential genotoxic effect of 4-OH catechol estrogens and the lifelong effect of variant genotypes on reaction rates, one would predict that woman B had a higher risk of developing breast cancer than woman A. Of course, these genetic risk factors will be modified by traditional, nongenetic risk factors such as age, parity, menopausal status, and body mass index.

In summary, we have defined the role of COMT in catechol estrogen metabolism and determined the difference in catalytic efficiency between wild-type and variant COMT. To prove the negative impact of variant COMT on breast cancer risk will require consideration of other enzymes participating in mammary estrogen metabolism as well as of traditional risk factors in large-scale molecular epidemiological studies.

ACKNOWLEDGMENTS

We thank Paul Bock for helpful discussions of the enzyme kinetics.

REFERENCES


7621
COMT AND ESTROGEN METABOLISM


Catechol-O-Methyltransferase (COMT)-mediated Metabolism of Catechol Estrogens: Comparison of Wild-Type and Variant COMT Isoforms

Sheila Dawling, Nady Roodi, Raymond L. Mernaugh, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/18/6716

Cited articles
This article cites 48 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/18/6716.full#ref-list-1

Citing articles
This article has been cited by 34 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/18/6716.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/61/18/6716.
Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.